Trials / Completed
CompletedNCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
Conditions
- Leukemia, Lymphoid
- Lymphoma, Non-Hodgkin
- Lymphoma, Mantle-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LOXO-305 | Administered orally. |
Timeline
- Start date
- 2021-05-14
- Primary completion
- 2023-04-10
- Completion
- 2025-12-29
- First posted
- 2021-04-19
- Last updated
- 2026-02-06
- Results posted
- 2024-07-16
Locations
22 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04849416. Inclusion in this directory is not an endorsement.